CNTB · XBRL financial data

Connect Biopharma Holdings financial statements, every quarter

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CNTB's year ends in late December)

In millions of dollars	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	—	—	year only	1*	0	0	0	0*	0	3
Research and development	—	—	year only	6*	7	9	11	11*	15	16
General and administrative	—	—	year only	4*	5	5	7	4*	5	4
Total operating expenses	—	—	year only	10*	11	13	18	16*	20	20
Operating income (loss)	—	—	year only	(10)*	(11)	(13)	(18)	(16)*	(20)	(18)
Other income (expense)	—	—	year only	(0)*	1	(0)	(0)	0*	(0)	0
Income tax expense (benefit)	—	—	year only	0*	0	0	0	0*	0	0
Net income (loss)	—	—	year only	(9)*	(10)	(13)	(17)	(15)*	(19)	(17)
Earnings per share, basic USD per share	—	—	—	(0.16)*	(0.19)	(0.23)	(0.31)	(0.27)*	(0.34)	(0.27)
Earnings per share, diluted USD per share	—	—	—	(0.16)*	(0.19)	(0.23)	(0.31)	(0.27)*	(0.34)	(0.27)
Weighted average shares, basic millions of shares	—	—	—	55*	55	55	56	56*	57	63
Weighted average shares, diluted millions of shares	—	—	—	55*	55	55	56	56*	57	63
Research and development millions of CNY	year only	year only	—	—	—	—	—	—	—	—
Operating profit (loss) millions of CNY	year only	year only	—	—	—	—	—	—	—	—
Profit (loss) millions of CNY	year only	year only	—	—	—	—	—	—	—	—

Fiscal quarters (CNTB's year ends in late December)

In millions of dollars	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	—	79	106	78	48	41	38	38	46	27
Short-term investments	—	—	13	15	36	31	17	6	0	4
Accounts receivable	—	—	0	1	0	0	0	0	0	3
Prepaid and other current assets	—	—	4	2	4	6	8	7	9	4
Total current assets	—	—	123	97	88	78	63	51	55	39
Property and equipment, net	—	—	4	4	4	4	4	4	4	4
Right-of-use asset	—	—	0	0	1	1	1	1	1	1
Total assets	—	—	127	101	93	83	67	56	60	43
Accounts payable	—	—	2	0	1	2	2	2	4	2
Accrued liabilities	—	—	9	8	7	8	9	11	12	14
Total current liabilities	—	—	25	8	9	11	11	14	17	16
Lease liability, non-current	—	—	0	0	1	1	0	0	0	0
Total liabilities	—	—	26	9	10	11	12	14	17	17
Accumulated deficit	—	—	(330)	(345)	(356)	(369)	(386)	(401)	(420)	(438)
Total stockholders' equity	—	158	101	92	83	71	55	42	43	27
Total liabilities and equity	—	—	127	101	93	83	67	56	60	43
Common shares outstanding (cover page) millions of shares	55	55	55	55	56	56	56	57	63	63
Cash and cash equivalents	268	79	106	—	—	—	—	—	—	—
Total current assets	275	156	121	—	—	—	—	—	—	—
Total assets	291	174	126	—	—	—	—	—	—	—
Total current liabilities	18	16	24	—	—	—	—	—	—	—
Total liabilities	19	17	25	—	—	—	—	—	—	—
Total equity millions of CNY	1,736	1,097	—	—	—	—	—	—	—	—
Total equity and liabilities	291	174	126	—	—	—	—	—	—	—

Fiscal quarters (CNTB's year ends in late December)

In millions of dollars	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	—	—	year only	(9)*	(10)	(13)	(17)	(15)*	(19)	(17)
Stock-based compensation	—	—	year only	1*	1	1*	1*	1*	1	1*
Depreciation and amortization	—	—	year only	0*	0	0*	0*	0*	0	0*
Net cash from operating activities	—	—	year only	(2)*	(10)	(13)*	(17)*	(11)*	(16)	(16)*
Purchases of property and equipment	—	—	year only	0*	0	0*	0*	0*	0	0*
Net cash from investing activities	—	—	year only	(16)*	(21)	5*	14*	11*	6	(4)*
Proceeds from issuing common stock	—	—	—	—	0	0*	—	—	0	0*
Net cash from financing activities	—	—	year only	0*	0	0*	0*	1*	18	1*
Net change in cash	—	—	year only	(19)*	(31)	(7)*	(3)*	1*	8	(19)*
Net cash from operating activities millions of CNY	year only	year only	—	—	—	—	—	—	—	—
Net cash from investing activities millions of CNY	year only	year only	—	—	—	—	—	—	—	—
Net cash from financing activities millions of CNY	year only	year only	—	—	—	—	—	—	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Connect Biopharma Holdings	27	2.8	(16)*	63.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
CervoMed	22	0	(6.9)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Actuate Therapeutics	4.4	not reported	(4.4)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Atara Biotherapeutics	3.2	0.6	(3.3)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Lite Strategy	5.7	not reported	(1.2)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
BriaCell Therapeutics	9.9	not reported	(6)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Actinium Pharmaceuticals	36	35	(5.2)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Fortress Biotech	197	19	(59)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	0	not reported	(0.2)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.